As of July 2000, a great deal has been learned over the past 18 months which he believes will serve the company well in the clinical trial phase of this exciting program. Boston Scientific is cautiously optimistic based on their data and the preliminary data being reported in other trials. Inc. According to Dr. William Hunter, Chairman and CEO of Angiotech, who shares Boston Scientific's enthusiasm for initiation of its clinical trial program, he believes that the initiation of human studies of the paclitaxel-coated NIR stent is a milestone event in stent technology. Boston Scientific is recognized as having expended substantial time and effort to develop a technically superior drug delivery stent. A provisional patent was filed for this work by principle investigator Mark Kester, Ph.D. associate professor of pharmacology.
Additional testing is planned with human clinical trials antcipated in two years or less.
This study is being conducted at Lenox Hill Hospital in New York under the direction of Drs. Jeffrey Moses and Martin Leon, and at the Texas Cardiac Center under the direction of Drs. Fawwaz M. Shoukfeh and Paul A. Overlie. This may been seen as a treatment modality to compliment coated stent technology. I clinical study and President of Cardiology Research Foundation, Lenox Hill Hospital.